The company's principal activity is to discover and develop new drugs for the treatment of viral diseases. The core technology platform is based on fusion inhibition aimed at treating disease by preventing viruses from entering host immune cells. Fuzeon is the company's first-generation HIV fusion inhibitor. It is used in combination of other anti-HIV drugs for the treatment of HIV-1 infection in treatment-experienced patients. T-1249 is the second-generation fusion inhibitor. The company is focused on the discovery and development of novel peptides with enhanced resistance profiles to target HIV strains that become resistant to other HIV fusion inhibitors.
